Acetylation phenotype is not associated with breast cancer.

In the present study, we have measured acetylation phenotype in 45 patients who had undergone surgical resection of a primary adenocarcinoma of the breast and in 48 patients or volunteer subjects with no breast disease. Phenotype was determined by measuring the ratio of N-acetylsulfamethazine to N-acetylsulfamethazine plus sulfamethazine in plasma 6 h after a p.o. dose of sulfamethazine. In the control group, there were 31 slow and 17 rapid acetylators, while in the breast patients, there were 25 slow and 20 rapid acetylators. The proportions of slow/rapid acetylators were not significantly different between the 2 groups (Pearson's chi 2 with Yates' correction = 0.45; P = 0.51). The data suggest that acetylation phenotype is not a useful risk prediction measurement in breast cancer.

[1]  D. Hein.  Genetic polymorphism and cancer susceptibility: Evidence concerning acetyltransferases and cancer of the urinary bladder , 1988, BioEssays : news and reviews in molecular, cellular and developmental biology.

[2]  D. Hein.  Acetylator genotype and arylamine-induced carcinogenesis. , 1988, Biochimica et biophysica acta.

[3]  F. Guengerich,et al.  The S-acetyl coenzyme A-dependent metabolic activation of the carcinogen N-hydroxy-2-aminofluorene by human liver cytosol and its relationship to the aromatic amine N-acetyltransferase phenotype. , 1987, Carcinogenesis.

[4]  P. Philip,et al.  Acetylator status and its relationship to breast cancer and other diseases of the breast. , 1987, European journal of cancer & clinical oncology.

[5]  R. PalmeiroTroitiño,et al.  Polymorphic hepatic acetylation in fibrocystic mastopathy , 1987 .

[6]  J. L. Ladero Quesada,et al.  [Polymorphic hepatic acetylation in fibrocystic mastopathy]. , 1987, Revista clinica espanola.

[7]  C. Jara,et al.  Hepatic acetylator polymorphism in breast cancer patients. , 1987, Oncology.

[8]  W. Weber.  The acetylator genes and drug response , 1987 .

[9]  W. McGuire,et al.  Role of steroid hormone receptors as prognostic factors in primary breast cancer. , 1986, NCI monographs : a publication of the National Cancer Institute.

[10]  F. Beland,et al.  DNA adducts formed from the probable proximate carcinogen, N-hydroxy-3,2' -dimethyl-4-aminobiphenyl, by acid catalysis or S-acetyl coenzyme A-dependent enzymatic esterification. , 1985, Carcinogenesis.

[11]  M. Pavlova,et al.  Acetylator phenotype in patients with breast cancer. , 1978, Oncology.